| Role |
Name |
Disclosure |
Details |
| Author | Guy E Brannon, MD, Associate Clinical Professor of Psychiatry, Louisiana State University Health Sciences Center; Director, Adult Psychiatry Unit, Chemical Dependency Unit, Clinical Research, Brentwood Behavior Health Company | AstraZeneca Takeda Wyeth Janssen | Details | | Coauthor | Kimberly S Carroll, MA, Clinical Research Coordinator, Brentwood Research Institute | Nothing to disclose | Details | | Medical Editor | Ronald C Albucher, MD, Chief Medical Officer, Westside Community Services; Consulting Staff, California Pacific Medical Center | Nothing to disclose | Details | | Pharmacy Editor | Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine | Nothing to disclose | Details | | Managing Editor | Eduardo Dunayevich, MD, Adjunct Assistant Professor, Department of Psychiatry, University of Cincinnati; Clinical Research Physician, Neuroscience, Lilly Research Laboratories | Nothing to disclose | Details | | CME Editor | Harold H Harsch, MD, Program Director of Geropsychiatry, Department of Geriatrics/Gerontology, Associate Professor, Department of Psychiatry and Department of Medicine, Froedtert Hospital, Medical College of Wisconsin | lilly BMS Forest Labs AstraZeneca Pfizer Northstar Novartis | Details | | Chief Editor | Stephen Soreff, MD, President of Education Initiatives, Nottingham, NH; Faculty, Metropolitan College of Boston University, Boston, MA | Nothing to disclose | Details |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Eduardo Dunayevich, Managing Editor |
The contributor discloses no conflict of interest. |
|